Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Director · Chief Executive Officer | August 19, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date August 19, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,485 |
Reported balance
After 2026-08-19 transaction · row 1
1 source rowRow 1 · 2026-08-19 · Gift · Disposed 528 · Balance 35,485 |
| Common StockSEC Table I · non-derivative | IndirectRevocable Trust | 43,803 |
Reported balance
Holding disclosure · report date 2026-08-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 43,803 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2020 Filed Jun 2, 2020 18:08 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $179.66 | $0.00 |
DisclosureSEC source: 0001127602-20-018382 · form4.xml · derivative · entry 2 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2030-05-29 F2 · shares: Stock Options vest in one-fourth increments on May 29, 2021, 2022, 2023 and 2024. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 18:08 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 1,948 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-018382 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,785 F1 · shares: Unvested restricted stock units vest in one-fourth increments on May 29, 2021, 2022, 2023 and 2024. Read SEC document |
| May 12, 2020 Filed May 13, 2020 12:18 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 780 | $165.74 | $129,277.20 |
DisclosureSEC source: 0001127602-20-016332 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,837 Read SEC document |
| February 26, 2020 Filed Feb 26, 2020 17:26 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 152 | $162.46 | $24,693.92 |
DisclosureSEC source: 0001127602-20-007867 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,617 Read SEC document |
| February 24, 2020 Filed Feb 24, 2020 17:38 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 322 | $173.64 | $55,912.08 |
DisclosureSEC source: 0001127602-20-007132 · form4.xml · nonDerivative · entry 3 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,769 Read SEC document |
| February 23, 2020 Filed Feb 24, 2020 17:38 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 315 | $173.64 | $54,696.60 |
DisclosureSEC source: 0001127602-20-007132 · form4.xml · nonDerivative · entry 2 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,091 Read SEC document |
| February 22, 2020 Filed Feb 24, 2020 17:38 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 308 | $173.64 | $53,481.12 |
DisclosureSEC source: 0001127602-20-007132 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,406 Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 14:43 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 900 | $172.05 | $154,845.00 |
DisclosureSEC source: 0001127602-20-005411 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,714 Read SEC document |
| February 07, 2020 Filed Feb 10, 2020 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 3,846 | $159.07 | $611,783.22 |
DisclosureSEC source: 0001127602-20-004561 · form4.xml · nonDerivative · entry 2 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,614 Read SEC document |
| February 07, 2020 Filed Feb 10, 2020 20:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 10,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004561 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,460 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on February 24, 2017. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 22:00 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 18 | $146.79 | $2,642.22 |
DisclosureSEC source: 0001127602-19-034705 · form4.xml · nonDerivative · entry 14 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,715 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 22:00 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 92 | $146.61 | $13,487.66 |
DisclosureSEC source: 0001127602-19-034705 · form4.xml · nonDerivative · entry 13 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,733 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 22:00 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $146.51 | $14,651.00 |
DisclosureSEC source: 0001127602-19-034705 · form4.xml · nonDerivative · entry 12 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,825 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 22:00 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 184 | $145.34 | $26,742.56 |
DisclosureSEC source: 0001127602-19-034705 · form4.xml · nonDerivative · entry 11 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,925 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 22:00 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 60 | $145.33 | $8,719.80 |
DisclosureSEC source: 0001127602-19-034705 · form4.xml · nonDerivative · entry 10 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,109 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 22:00 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 89 | $145.32 | $12,933.48 |
DisclosureSEC source: 0001127602-19-034705 · form4.xml · nonDerivative · entry 9 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,169 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 22:00 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 50 | $145.29 | $7,264.50 |
DisclosureSEC source: 0001127602-19-034705 · form4.xml · nonDerivative · entry 8 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,258 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 22:00 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 64 | $145.29 | $9,298.24 |
DisclosureSEC source: 0001127602-19-034705 · form4.xml · nonDerivative · entry 7 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,308 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 22:00 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 118 | $145.28 | $17,143.04 |
DisclosureSEC source: 0001127602-19-034705 · form4.xml · nonDerivative · entry 6 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,372 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 22:00 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 11 | $145.27 | $1,597.97 |
DisclosureSEC source: 0001127602-19-034705 · form4.xml · nonDerivative · entry 5 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,490 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 22:00 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 80 | $145.26 | $11,620.80 |
DisclosureSEC source: 0001127602-19-034705 · form4.xml · nonDerivative · entry 4 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,501 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 22:00 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 97 | $145.25 | $14,089.25 |
DisclosureSEC source: 0001127602-19-034705 · form4.xml · nonDerivative · entry 3 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,581 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 22:00 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 50 | $145.25 | $7,262.25 |
DisclosureSEC source: 0001127602-19-034705 · form4.xml · nonDerivative · entry 2 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,678 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 22:00 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 38 | $145.24 | $5,518.93 |
DisclosureSEC source: 0001127602-19-034705 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,728 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 87 | $145.21 | $12,633.27 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 30 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,766 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 80 | $145.18 | $11,614.00 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 29 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,853 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 188 | $145.16 | $27,290.08 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 28 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,933 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 217 | $145.11 | $31,488.87 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 27 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,121 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 136 | $145.10 | $19,732.92 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 26 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,338 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 36 | $145.08 | $5,222.70 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 25 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,474 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 156 | $145.06 | $22,629.36 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 24 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,510 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $145.05 | $14,505.00 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 23 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,666 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 9 | $145.03 | $1,305.27 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 22 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,766 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 80 | $145.03 | $11,602.00 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 21 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,775 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 88 | $144.99 | $12,759.12 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 20 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,855 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 3 | $144.97 | $434.91 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 19 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,943 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 93 | $144.94 | $13,478.96 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 18 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,946 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 106 | $144.92 | $15,361.52 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 17 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,039 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 81 | $144.91 | $11,737.31 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 16 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,145 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 5 | $144.88 | $724.40 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 15 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,226 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 29 | $144.88 | $4,201.38 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 14 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,231 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 176 | $144.87 | $25,497.12 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 13 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,260 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 124 | $144.84 | $17,960.16 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 12 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,436 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 89 | $144.83 | $12,889.87 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 11 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,560 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 149 | $144.80 | $21,575.20 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 10 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,649 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 178 | $144.79 | $25,772.62 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 9 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,798 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 194 | $144.77 | $28,085.38 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 8 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,976 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 92 | $144.76 | $13,317.92 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 7 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,170 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 78 | $144.74 | $11,289.72 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 6 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,262 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 21 | $144.72 | $3,039.12 |
DisclosureSEC source: 0001127602-19-034703 · form4.xml · nonDerivative · entry 5 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,340 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.